Magnesium Sulfate and Calcium
Learning objectives
After completing this chapter, you should be able to distinguish the maternal and fetal indications for magnesium sulfate; explain how magnesium affects neuromuscular transmission; safely continue a loading dose or maintenance infusion during transport; identify early toxicity from clinical findings; compare calcium gluconate with calcium chloride; anticipate neonatal effects; and build a practical rescue plan before departure.
Opening transport scenario
A 32-year-old patient at 30 weeks’ gestation is being transferred for severe preeclampsia. She received a magnesium sulfate loading dose and is now receiving a maintenance infusion. Her blood pressure is controlled after antihypertensive therapy, but urine output has fallen to 18 mL during the past hour. During loading, she becomes increasingly somnolent, her respiratory rate falls from 18/min to 10/min, and patellar reflexes become difficult to elicit. The transport team must decide whether this is expected medication effect, evolving magnesium toxicity, worsening neurologic disease, or another cause of deterioration.
1. What magnesium sulfate does—and does not do
Magnesium sulfate reduces neuromuscular excitability and central nervous system irritability. In obstetric care it is used primarily for seizure prevention and treatment in preeclampsia/eclampsia and for fetal neuroprotection when early preterm birth is anticipated. It is not an antihypertensive; severe blood pressure still requires a separate first-line antihypertensive agent. Magnesium is also not preferred as routine tocolysis merely because contractions are present.
CH13-VIS-01Maternal and fetal indications for magnesium sulfate
A side-by-side visual distinguishing maternal seizure indications from fetal neuroprotection and explicitly separating magnesium from antihypertensive and routine tocolytic therapy.
See the accompanying chapter visual-aids Markdown file for the detailed description, accessibility text, production specifications, and generation prompt.
Maternal indications
- Treatment of an eclamptic seizure and prevention of recurrent seizures.
- Seizure prophylaxis in preeclampsia with severe features when ordered by the obstetric team.
- Continuation during labor and the postpartum period according to the clinical plan and local policy.
Fetal indication
When early preterm delivery is likely, magnesium sulfate may reduce the risk of cerebral palsy among surviving infants. ACOG and SMFM support institutional protocols for fetal neuroprotection, commonly when delivery before 32 weeks is anticipated. The decision is linked to gestational age, likelihood and timing of delivery, neonatal plan, and contraindications.
2. Common clinical regimens
Regimens vary by institution. The transport clinician must verify the exact order, concentration, loading-dose completion, maintenance rate, total dose, indication, and stop criteria before movement.
| Use | Common educational regimen | Transport priorities |
|---|---|---|
| Eclampsia treatment or severe-preeclampsia prophylaxis | Loading dose commonly 4–6 g IV over about 20–30 minutes, followed by 1–2 g/hour. | Confirm seizure history, loading-dose start and completion times, maintenance rate, renal function, respiratory status, reflexes, and calcium availability. |
| Recurrent seizure despite magnesium | An additional 2–4 g IV may be ordered, usually given slowly with close respiratory and hemodynamic monitoring. | Support airway and ventilation, verify that the seizure is truly recurrent eclampsia, and prepare for escalation if seizure persists. |
| Fetal neuroprotection | Institution-specific regimen, often a 4–6 g loading dose followed by 1–2 g/hour until birth or a protocol-defined stop time. | Confirm gestational age, delivery likelihood, neonatal plan, and whether transport delay is appropriate. |
3. Monitoring during transport
Clinical monitoring is more important than chasing a number in an otherwise stable patient. Serum magnesium concentrations are useful when renal dysfunction, prolonged infusion, absent reflexes, respiratory depression, or other concern is present, but toxicity is recognized clinically.
| Assessment | Why it matters | Concerning trend |
|---|---|---|
| Respiratory rate and effort | Respiratory depression is a major toxicity endpoint. | Falling rate, shallow respirations, rising EtCO₂, new oxygen requirement, or inability to protect the airway. |
| Deep-tendon reflexes | Loss of reflexes often precedes severe respiratory or cardiac toxicity. | Progressive diminution or absence compared with baseline. |
| Urine output | Magnesium is cleared primarily by the kidneys. | Oliguria or declining output, especially with rising creatinine. |
| Mental status | Somnolence may be medication effect, toxicity, seizure-related, stroke, or severe disease. | Progressive lethargy, confusion, or inability to maintain airway. |
| Blood pressure and pulse | Hypotension and conduction effects may occur with toxicity or coadministered drugs. | New hypotension, bradycardia, heart block, or widening QRS. |
| Fetal status | Maternal perfusion and medication exposure affect fetal response. | Persistent bradycardia, loss of reassuring features, or deterioration after maternal change. |
Which single bedside trend should immediately raise concern in a patient receiving magnesium who has declining renal function?
Answer: Falling respiratory rate or loss of deep-tendon reflexes is a high-priority toxicity finding. Declining urine output increases the risk because magnesium clearance is reduced.
4. Magnesium toxicity
Toxicity exists on a continuum. Therapeutic and toxic concentration ranges overlap among patients, so the transport clinician should act on clinical deterioration rather than wait for a laboratory result. Increasing magnesium concentration is generally associated with flushing and nausea, diminished reflexes, somnolence, respiratory depression, conduction abnormalities, paralysis, and cardiac arrest.
CH13-VIS-02Magnesium toxicity progression and rescue actions
A horizontal progression from therapeutic effect through loss of reflexes, respiratory depression, conduction disturbance, and arrest, paired with escalating transport actions.
See the accompanying chapter visual-aids Markdown file for the detailed description, accessibility text, production specifications, and generation prompt.
Immediate response
- Stop the magnesium infusion and preserve the tubing and pump settings for reconciliation.
- Call for help and notify medical direction and the receiving obstetric team.
- Support airway, oxygenation, and ventilation; use waveform capnography when indicated.
- Reassess reflexes, urine output, vital signs, ECG, fetal status, renal function, and the possibility of another diagnosis.
- Prepare and administer calcium according to order or emergency protocol.
- Consider critical-care escalation, vasopressor support, and dialysis consultation for severe toxicity with renal failure.
5. Calcium rescue: gluconate versus chloride
Calcium antagonizes the neuromuscular and cardiac effects of magnesium but does not remove magnesium from the body. Continued supportive care and reassessment are essential.
| Feature | Calcium gluconate | Calcium chloride |
|---|---|---|
| Common obstetric rescue role | Traditional first-line antidote for symptomatic magnesium toxicity. | Acceptable alternative in critical care when ordered and appropriately administered. |
| Common adult emergency dose | 1 g IV, typically 10 mL of a 10% solution, administered slowly with ECG monitoring. | 1 g IV contains substantially more elemental calcium than 1 g calcium gluconate; dose and route must be verified. |
| Access considerations | Less caustic and generally preferred through peripheral IV access. | More vesicant; central access is preferred when feasible because extravasation can cause severe tissue injury. |
| Key reminder | May need repeat dosing if symptoms persist and medical direction orders it. | Do not treat the two calcium salts as milligram-for-milligram equivalents. |
6. Renal dysfunction and prolonged infusion
Pregnancy normally lowers serum creatinine because glomerular filtration rises. A creatinine that appears “normal” on an adult reference range may therefore represent impaired renal function in pregnancy. Oliguria, acute kidney injury, or prolonged infusion increases the risk of accumulation. The team should verify whether the infusion rate has been reduced, whether a serum level is required, and what specific findings trigger discontinuation.
7. Important interactions and confounders
- Neuromuscular blocking agents may have prolonged or intensified effects in the presence of magnesium.
- Opioids, sedatives, anesthetics, and severe neurologic disease can compound respiratory depression and altered mental status.
- Nifedipine and other vasodilators may contribute to hypotension; concurrent use is not automatically prohibited but requires close monitoring.
- Pulmonary edema, aspiration, stroke, recurrent seizure, hypoglycemia, and postictal states can mimic or coexist with toxicity.
- Calcium-channel blockers and magnesium should never distract from assessing hemorrhage, sepsis, cardiomyopathy, or embolic disease.
8. Fetal and neonatal considerations
Maternal magnesium crosses the placenta. The exposed newborn—sometimes informally called a “magnesium baby”—may have hypotonia, weak respiratory effort, poor feeding, or depressed reflexes. Most effects are managed with warmth, stimulation, effective ventilation, and neonatal support rather than routine calcium administration. The transport team should alert the receiving and neonatal teams to the indication, dose, timing, maternal renal function, and any maternal toxicity.
CH13-VIS-03Maternal magnesium exposure and neonatal transition
A transport-focused visual showing the information pathway from maternal infusion history to neonatal preparation for tone, respiratory effort, thermoregulation, and ventilation support.
See the accompanying chapter visual-aids Markdown file for the detailed description, accessibility text, production specifications, and generation prompt.
9. Predeparture magnesium checklist
- Indication clearly stated: seizure treatment, seizure prophylaxis, or fetal neuroprotection.
- Loading dose, completion time, concentration, maintenance rate, cumulative dose, and stop time verified.
- Respiratory rate, SpO₂, lung sounds, mental status, reflexes, urine output, BP, ECG as indicated, and fetal status documented.
- At least one reliable IV line identified; magnesium tubing traced and secured.
- Calcium rescue medication, airway equipment, suction, ventilation equipment, and pump battery available.
- Receiving team knows current infusion, latest assessment, renal function, and any concern for toxicity.
- Diversion threshold and escalation plan are explicit.
10. Evolving case study
Phase 1: Departure
The patient at 30 weeks is receiving 2 g/hour after a 6 g loading dose. Respiratory rate is 16/min, reflexes are 2+, urine output was 45 mL during the prior hour, and fetal status is reassuring. The team verifies calcium gluconate, ventilation equipment, and a functional pump battery.
Phase 2: Deterioration
Forty minutes later, respiratory rate is 9/min, EtCO₂ is rising, reflexes are absent, and urine output is 10 mL for the hour. The patient is increasingly difficult to arouse. Magnesium is stopped, assisted ventilation is prepared, the receiving center and medical direction are contacted, and calcium is administered according to order.
Phase 3: Reassessment
Respiratory effort improves after support and calcium. The team continues close ECG, respiratory, hemodynamic, and fetal monitoring. Because calcium does not remove magnesium, the receiving team is advised that recurrent toxicity and dialysis consideration remain possible.
Why is a normal blood pressure not enough to rule out magnesium toxicity?
Answer: Magnesium toxicity is primarily recognized through neuromuscular, respiratory, renal, and cardiac findings. Blood pressure may remain normal until toxicity is advanced or may be affected by other therapies.
11. High-yield chapter summary
- Magnesium treats or prevents seizures and may provide fetal neuroprotection; it is not an antihypertensive.
- Verify the indication before interpreting the regimen.
- Clinical monitoring includes respirations, reflexes, urine output, mental status, hemodynamics, ECG when indicated, and fetal status.
- Renal dysfunction greatly increases toxicity risk.
- Loss of reflexes and respiratory depression are high-priority warning signs.
- Stop the infusion, support ventilation, notify the team, and prepare calcium when toxicity is suspected.
- Calcium gluconate is less caustic peripherally; calcium chloride provides more elemental calcium but has greater extravasation risk.
- Calcium antagonizes toxicity but does not eliminate magnesium.
- Maternal exposure can cause neonatal hypotonia and respiratory depression.
- A transport-ready rescue plan must exist before movement.
References
- International Board of Specialty Certification. Maternal Fetal Transport Microcredential Candidate Handbook. Updated April 2026.
- American College of Obstetricians and Gynecologists. Gestational Hypertension and Preeclampsia. Practice Bulletin No. 222. 2020.
- American College of Obstetricians and Gynecologists; Society for Maternal-Fetal Medicine. Magnesium Sulfate Before Anticipated Preterm Birth for Neuroprotection.
- Society for Maternal-Fetal Medicine. Diagnosis and Management of Fetal Growth Restriction. Consult Series #52.
- American Heart Association. 2025 Guidelines for Neonatal Resuscitation.
Twenty-question magnesium sulfate and calcium quiz
Immediate rationales are shown in study mode, and your score is stored locally.